Article Text

PDF
Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism
  1. Phil Hyu Lee1,
  2. Seung Hyeon Yeo1,
  3. Seok Woo Yong1,
  4. Yun Joong Kim2
  1. 1
    Department of Neurology, Ajou University School of Medicine, Suwon, South Korea
  2. 2
    Department of Neurology, Hallym University College of Medicine, Anyang, South Korea
  1. Dr Phil Hyu Lee, Department of Neurology, Ajou University School of Medicine, Woncheon-dong San 5, Paldal-gu, Suwon, Gyeonggi-do, 442-749, Korea; phisland{at}chol.com

Abstract

We investigated olfactory function and its relation to cardiac 123I-metaiodobenzylguanidine (MIBG) uptake in 15 patients with drug induced parkinsonism (DIP). The mean Cross Cultural Smell Identification (CCSI) score was significantly greater in patients with DIP than in those with Parkinson’s disease (PD: 6.9 (1.6) vs 4.4 (2.2); p<0.001); however, the mean CCSI score in patients with DIP was not significantly different from controls. One patient with DIP, whose CCSI score was significantly reduced, also exhibited decreased cardiac MIBG uptake. DIP patients with CCSI scores within the normal range had normal cardiac MIBG uptake. Our study suggests that an olfactory function test may be a useful tool for detecting DIP unrelated to PD and for identifying patients with DIP who have subclinical PD.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None

  • Abbreviations:
    DIP
    drug induced parkinsonism
    CCSI
    Cross Cultural Smell Identification
    H/M ratio
    heart/mediastinum ratio
    MIBG
    metaiodobenzylguanidine
    PD
    Parkinson’s disease
    PET
    positron emission tomography

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.